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Tissue factor pathway inhibitor anticoagulant activity: risk for
venous thrombosis and effect of hormonal state
Tissue factor pathway inhibitor 1 (TFPI) is the physiological
inhibitor of blood coagulation initiated by tissue factor (TF).
There is now convincing evidence that TFPI plays a key role in
regulating blood coagulation in vivo. First, TFPI gene knock-
out mice suffered abnormal intrauterine development and
death (Huang et al, 1997). Secondly, immunodepletion of
TFPI in rabbits significantly decreased the threshold by which
TF may trigger coagulation and induce disseminated intravas-
cular coagulation (Sandset et al, 1991a,b). Thirdly, high doses
of recombinant TFPI protected against various experimentally
induced thrombotic disorders (Holst et al, 1993; Kaiser &
Fareed, 1996; Bajaj & Bajaj, 1997). Moreover, it has recently
been reported that low levels of TFPI is a risk factor for both
venous and arterial thrombosis (Dahm et al, 2003; Morange
et al, 2004). Therefore, it is intriguing that familial TFPI
mutations associated with low levels of TFPI and increased risk
of thrombosis have not yet been convincingly reported
(Sandset & Bendz, 1997).
In contrast to other coagulation inhibitors, e.g. antithrom-
bin and protein C, the intravascular distribution of TFPI
in vivo is rather complex. Most intravascular TFPI is free full-
length TFPI, which is associated with the vascular endothelium
and which may be released by heparin and other negatively
charged polyanions (Sandset et al, 2000). A small amount of
free full-length TFPI is also found in circulating blood, but
plasma contains mostly truncated forms of TFPI, which is to a
great extent, bound to lipoproteins (Novotny et al, 1989;
Lindahl et al, 1991; Hansen et al, 1994). The role of different
forms of TFPI are not well known, but as full-length TFPI
exerts a much stronger anticoagulant effect in diluted
prothrombin time (dPT)-based assays than truncated and
lipoprotein-associated TFPI (Lindahl et al, 1991; Nordfang
et al, 1991; Hansen et al, 1995), it has been suggested that full-
length TFPI is biologically more important in vivo. The
complex distribution and functional aspects of TFPI raises the
important question of how to detect TFPI deficiency and
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Summary
Full-length tissue factor pathway inhibitor (TFPI) is assumed to be
biologically more important than truncated TFPI because of its stronger
anticoagulant effect in the diluted prothrombin time (dPT) assay. We have
developed a dPT-based assay for TFPI anticoagulant activity. Here, we report
the effect of hormonal state on TFPI anticoagulant activity and whether TFPI
anticoagulant activity assesses the risk for deep-vein thrombosis (DVT) better
than conventional TFPI assays. We undertook a case-control study of 474
patients with DVT and 474 controls and compared the odds ratio (OR) for
DVT for those with low TFPI anticoagulant activity with the ORs obtained
for TFPI free and total antigen, and TFPI chromogenic substrate activity.
Hormonal state affected clot time in dPT, but this effect was ameliorated by
anti-TFPI antibodies. Low TFPI anticoagulant activity gave an OR of 1Æ5
(0Æ97–2Æ1) for DVT, similar to the ORs obtained with conventional TFPI
assays, ranging from 1Æ2 to 1Æ4. Individuals low in both the activity assays
obtained an OR of 5Æ9 (1Æ7–20). We concluded that the effect of hormonal
state on dPT was mediated through TFPI, and a dPT-based assay of TFPI
anticoagulant activity did not assess the risk for DVT better than
conventional TFPI assays.
Keywords: deep-vein thrombosis, diluted prothrombin time, thrombophilia,
tissue factor, tissue factor pathway inhibitor.
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functional defects in vivo, and it has been speculated that a
dPT-based assay of TFPI might reveal TFPI deficiencies that
other assays fail to detect (Sandset & Bendz, 1997).
Currently published assays detect free full-length TFPI
(TFPI-free antigen) or all forms of TFPI (TFPI total antigen)
in plasma (Table I). Functional assays involve prolonged
incubation of TFPI in plasma with TF, factor VIIa (FVIIa)
and factor Xa (FXa), which allows the formation of inactive
TFPI/FXa/TF/FVIIa inhibitory complexes, and residual TF/
FVIIa catalytic activity is determined with a substrate, e.g. FX
and a chromogenic substrate or tritium-labelled factor IX.
Such functional assays correlated strongly with TFPI total
antigen levels (Bendz et al, 2000; Dahm et al, 2005) and may
be rather insensitive to functional defects of TFPI.
We have recently developed a novel assay of TFPI anticoa-
gulant activity (Dahm et al, 2005), which is based on the
ability of TFPI to prolong the clotting time after initiation of
coagulation with a low concentration of TF, i.e. a dPT assay. In
this assay, dPT is run both in the presence and in the absence
of TFPI neutralising antibodies. The shortening of clotting
times in the presence of TFPI antibodies reflects TFPI
anticoagulant activity. The TFPI anticoagulant activity assay
is specific for full-length TFPI and insensitive to truncated
TFPI. In the present study, we have evaluated the role of TFPI
anticoagulant activity as a risk factor for the development of
deep-vein thrombosis (DVT) and studied the effect of
hormonal state on dPT and TFPI using blood samples
collected in the Leiden Thrombophilia Study (LETS).
Patients and methods
Leiden thrombophilia study – study population and blood
sampling
The design of the LETS case–control study has previously been
described in detail (Koster et al, 1993). Briefly, 474 patients
with an objectively diagnosed first time DVT were compared
with 474 sex- and age-matched controls. In a previous report,
we reported TFPI free and total antigen and TFPI chromogenic
substrate activity data in 473 patients and 473 control subjects
(Dahm et al, 2003). The current report concerns data on TFPI
anticoagulant activity in 452 cases and 439 controls where
blood samples were available for analysis. The patients were
selected from three anticoagulation clinics in the Netherlands.
The controls were acquaintances of the patients or partners of
other patients. Patients with known malignancies were exclu-
ded and all patients were younger than 70 years of age. The
Leiden University Medical Centre ethics committee approved
the study protocol, and all participants gave informed consent
according to the Declaration of Helsinki. Blood samples were
taken between 6 and 56 months after the thrombosis was
diagnosed, hence most patients had finished their anticoagu-
lant treatment at the time of blood sampling. Whole blood
(0Æ9 v) was collected from the antecubital vein into Sarstedt
Monovette tubes (Sarstedt, Nu¨mbrecht, Germany) containing
0Æ106 mol/l of trisodium citrate (0Æ1 v). Plasma was prepared
by centrifugation for 10 min at 2000 g at room temperature
and stored in aliquots at )70C until assayed.
TFPI assays
The ‘TFPI anticoagulant activity’ assay was based on the assay
of dPT in the presence and the absence of neutralising TFPI
antibodies (anti-TFPI IgG) as reported in detail elsewhere
(Dahm et al, 2005). Briefly, 32 ll of plasma was incubated
with 8 ll Tris-buffered saline or 8 lL anti-TFPI IgG and
incubated for 4–6 min at room temperature. Thirty microlitres
of TF (Innovin4, diluted 1/200; Dade Behring, Marburg,
Germany) was then added and incubated for 3 min at 37C.
Finally, 30 ll 35 mmol/l CaCl2 was added and the time to
clotting recorded with the Amelung KC4 coagulometer
(Trinity Biotech, Bray, Ireland). Clotting time in the absence
of anti-TFPI IgG was approximately 75 s, which was reduced
by approximately 7–8 s in the presence of anti-TFPI IgG in
normal reference plasma. Test results were expressed as a TFPI
anticoagulant ratio of the dPT recorded in the absence of anti-
TFPI IgG on the dPT in the presence anti-TFPI IgG. Both dPTs
as well as the TFPI anticoagulant ratio were normalised against
results obtained with the normal reference plasma to minimise
the effects of variations in assay conditions, e.g. day-to-day and
batch-to-batch variations or reagents. Thus, a low normalised
dPT meant a short dPT, while a high normalised dPT meant a
Table I. Overview of the assays of circulating TFPI.
TFPI assay Measures what
Strongly correlated TFPI-free antigen Amount of full-length TFPI
TFPI anticoagulant
activity
The ability of full-length TFPI to inhibit FXa.
Insensitive to truncated TFPI
Not strongly correlated TFPI chromogenic
substrate activity
The ability of the total TFPI, i.e. full-length and
truncated TFPI to inhibit TF/FVIIa
Strongly correlated TFPI total antigen Amount of full-length and truncated TFPI
TFPI, tissue factor pathway inhibitor; FXa, factor Xa; TF, tissue factor;
FVIIa, factor VIIa.
n
n
n
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long dPT. Correspondingly, low normalised TFPI anticoagu-
lant ratios indicated low TFPI anticoagulant potential, whereas
high ratios indicated high TFPI anticoagulant potential.
Because of the limited amounts of plasma, most blood samples
were assayed in a single run. Interday coefficient of variation
(CV) was 2Æ8% and intraday CV was between 0Æ5% and 1Æ5%.
The ‘TFPI free antigen and TFPI total antigen’ were assayed
in duplicate with commercial enzyme-linked immunosorbent
assays (ELISAs) (Asserachrom Free TFPI and Asserachrom
Total TFPI; Diagnostica Stago, Asnie´re, France), described in
detail elsewhere (Dahm et al, 2003). Inter- and intra-assay
variability, measured as CV was 4Æ4% and 2Æ9% for TFPI total
antigen, and 4Æ9% and 3Æ8% for TFPI free antigen respectively.
Bound TFPI was calculated as the difference between TFPI
total antigen and TFPI-free antigen. The fraction of free, full-
length TFPI in plasma was calculated as the proportion of
TFPI-free antigen in TFPI total antigen.
The ‘TFPI chromogenic substrate activity’ was assayed in
duplicate with an inhouse two-stage chromogenic substrate
assay, as described earlier (Bendz et al, 2000). In this assay,
TFPI activity was determined by the quantification of residual
TF/FVIIa catalytic activity after the incubation of diluted
plasma (containing TFPI) with TF, FVIIa in excess of TF-
binding sites, and FXa. Inter- and intra-assay variability was
3Æ5% and 1Æ4% respectively.
Statistics
The controls represent the general population and were used to
estimate the intravascular distribution of TFPI and to study the
effect of hormonal state on dPT and the levels of TFPI.
To compare women using oral contraceptives (OC) with
non-users, a special selection described earlier was made to
obtain comparable groups (van Hylckama Vlieg et al, 2000).
Non-menopausal women between 15 and 49 years of age were
included. Women, who at the index date (similar date as date
of thrombosis for patients) were pregnant, within 30 days
postpartum, had a recent miscarriage or had used only depot
contraceptives were excluded. A total of 142 control subjects
were included in this analysis. To compare women not using
OC with postmenopausal women, the same selection was used
except that one postmenopausal woman who had used depot
contraceptives was excluded.
To study the role of different forms of TFPI we calculated
the risk for thrombosis associated with low TFPI for the
different TFPI parameters. OC decrease TFPI levels in blood
(Dahm et al, 2003). As OC is a well-known risk factor for
DVT, many of the OC users with DVT stopped their use of OC
at the time of diagnosis, and supposedly had higher TFPI at the
time of blood sampling 6–56 months later. However, in the
control group there was almost no change in OC use, hence
OC users were omitted from the risk calculations (Dahm et al,
2003). Individuals on oral anticoagulation were excluded
because of their effect on dPT, three patients with extreme
TFPI anticoagulant values were excluded (Dahm et al, 2005).
In addition, a few individuals had missing residual blood
samples available for analysis. Therefore, this study involves
362 patients and 363 controls, which is less than in our
previous report (Dahm et al, 2003). ‘Low TFPI’, for all TFPI
parameters, was defined as TFPI below the 10th percentile
among the controls as reported earlier (Dahm et al, 2003). In
the calculation of the odds ratio (OR) for DVT in those who
were low in both TFPI anticoagulant activity and TFPI
chromogenic substrate activity, ‘low TFPI’ was defined as
those individuals with TFPI below the 10th percentile in both
assays at the same time, all others (i.e. those who had low TFPI
in only one or none of the assays) were defined as having ‘high
TFPI’.
The TFPI values within groups of controls are reported as
mean values and 95% confidence intervals (CI). Differences in
mean values of normalised dPT between groups of controls
with different hormonal state were tested with Student’s t-test.
P values below 0.05 were considered significant.
Results
Low TFPI anticoagulant activity as a risk factor for DVT
Normalised TFPI anticoagulant ratio below the 10th percentile
gave an OR for DVT of 1Æ5 (95% CI 0Æ97–2Æ4) (Table II). To
examine whether the TFPI anticoagulant activity assay assessed
the risk for DVT differently from the other TFPI assays, ORs
for DVT for TFPI levels below the 10th percentile were
calculated in the same selection of cases and controls for TFPI
free and total antigen, bound TFPI and TFPI chromogenic
Table II. Crude odds ratios for deep-vein thrombosis for normalised
tissue factor pathway inhibitor (TFPI) anticoagulant ratio (n-TFPIac
ratio), TFPI free antigen, TFPI total antigen, TFPI chromogenic sub-
strate activity (TFPIcs activity) and bound TFPI.
Patients
(n ¼ 362)
Controls
(n ¼ 363)
Odds ratio
(95% CI)
n-TFPIac ratio
>10th percentile 310 327 1Æ5 (0Æ97–2Æ4)
£10th percentile 52 36
TFPI-free antigen
>10th percentile 316 327 1Æ3 (0Æ83–2Æ1)
£10th percentile 46 36
TFPI total antigen
>10th percentile 314 326 1Æ3 (0Æ85–2Æ1)
£10th percentile 48 37
TFPIcs activity
>10th percentile 317 324 1Æ2 (0Æ75–1Æ9)
£10th percentile 45 39
Bound TFPI
>10th percentile 313 327 1Æ4 (0Æ90–2Æ2)
£10th percentile 49 36
n-TFPIac ratio and TFPIcs activity
>10th percentile 345 360 5Æ9 (1Æ7–20)
£10th percentile 17 3
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substrate activity. The ORs ranged from 1Æ2 to 1Æ4 (Table II),
i.e. the risk for DVT was quite similar in all TFPI assays and
none of the assays proved more predictive in assessing the risk
for DVT. ORs in hormonal subgroups (men, postmenopausal
women and premenopausal women not using OC) were in the
same range for all assays (data not shown).
Those individuals who had low TFPI in both the activity
assays, i.e. low TFPI chromogenic substrate activity and low
normalised TFPI anticoagulant ratio, had an OR of 5Æ9 (1Æ7–
20), relative to those who were only low in one or low in
neither assay (Table II). Only three of the 363 (c. 1%) controls
had low TFPI in both assays, in accordance with the expected
prevalence based on the frequency of low values in each test of
around 10%, which indicates that very few in the general
population are affected by the risk for thrombosis due to low
levels of TFPI in both activity assays. However, a separate study
of the OC users in the healthy control group (who were
excluded from other analyses, see Patients and methods)
showed that 31 of 57 OC users (c. 54%) had low TFPI in both
assays.
The effects of OC and hormonal state
Hormonal state had an explicit effect on the dPT. Premeno-
pausal OC users had a shorter normalised dPT than non-users,
and non-users had a shorter normalised dPT than postmen-
opausal women, who again had a shorter dPT than men. When
TFPI was neutralised by anti-TFPI antibodies the difference in
dPT between the hormonal subgroups were almost abolished,
only some effect of male sex on dPT persisted (Table III),
which means that the effect of hormonal state on dPT was
mainly mediated through the effect of hormonal state on
plasma levels of TFPI. Hormonal state had a corresponding
effect on the normalised TFPI anticoagulant ratio. OC users
had the lowest ratios and postmenopausal women and men
had highest ratios (Table IV).
Estimation of the percentage-free TFPI of the total
circulating TFPI in plasma
As the TFPI anticoagulant activity is a measure of the
anticoagulant activity of the fraction of free full-length TFPI
in plasma we investigated the effect of hormonal state on the
fraction of free TFPI. The control group had a mean TFPI-free
antigen/TFPI total antigen ratio of 0Æ19 (standard deviation
0Æ056, range 0Æ070–0Æ38). In other words, 19% of the total
circulating TFPI was free full-length TFPI, but with large inter-
individual variation mainly due to hormonal state. In OC
users, approximately 13% was free full-length TFPI, while
fertile women not using OC had a mean of 18% free full-length
TFPI. Postmenopausal women and men had approximately
20% of their TFPI in the free form (Table V). Thus, it seems
that hormonal state had a stronger effect on full-length than
truncated TFPI in plasma.
Discussion
We and other investigators have previously hypothesised that
full-length TFPI plays an important biological role in vivo
because of its strong inhibitory effect in dPT-based assays
(Lindahl et al, 1991; Nordfang et al, 1991; Hansen et al, 1995;
Sandset & Bendz, 1997). Hence, a dPT-based assay that can
exclusively detect the functional activity of full-length TFPI
might have the potential to detect TFPI deficiencies that other
assays so far may have failed to detect (Sandset & Bendz, 1997;
Ariens, 2005). Our current data do not support this hypothe-
sis. TFPI anticoagulant activity below the 10th percentile was
associated with a mildly increased risk for DVT, which was
similar to the risks associated with levels of TFPI below the
10th percentile detected in conventional TFPI assays.
We have recently shown that the plasma levels of TFPI-free
antigen and TFPI anticoagulant activity are closely associated,
and that the levels of TFPI chromogenic substrate activity and
TFPI total antigen also are closely associated (Table I) (Dahm
et al, 2005). Therefore, it hardly seems necessary to use both
the antigen assays and the activity assays in population-based
studies. Measurements of TFPI free and total antigen will give
a good impression of the TFPI anticoagulant activity and the
TFPI chromogenic substrate activity, respectively, as well as of
the risks for DVT associated with each assay. But in individuals
with a suspected mutation, dual antigen and activity assay
would be of interest to detect a dysfunctional protein.
The TFPI anticoagulant activity and TFPI chromogenic
substrate activity are not very closely associated and do
probably reflect different targets of inhibition in vivo (Dahm
et al, 2005). Based on this and other reports on the kinetics of
the inhibition of FXa and TF/FVIIa by TFPI (Huang et al,
1993; Lindhout et al, 1994, 1995; Lockett & Mast, 2002), we
suggest that the TFPI anticoagulant activity is a measure of the
inhibition of FXa, while the TFPI chromogenic substrate
activity is a measure of the inhibition of the TFPI/FXa complex
(Table I). TFPI anticoagulant activity and TFPI chromogenic
substrate activity may therefore be considered to be independ-
ent risk factors for thrombosis. Moreover, both activity assays
yielded approximately the same risk for DVT even though they
were not closely associated [Table I and (Dahm et al, 2005)].
We have tentatively calculated the risk for DVT for the
Table III. Mean normalised diluted prothrombin time (dPT) with and
without inhibiting anti-tissue factor pathway inhibitor (anti-TFPI)
antibodies.
OC+
(n ¼ 51)
OC)
(n ¼ 91)
Postmenopausal
women (n ¼ 83)
Men
(n ¼ 182)
N-dPT 1Æ02** 1Æ12** 1Æ16** 1Æ20**
N-dPT +
anti-TFPI
1Æ08 ns 1Æ10 ns 1Æ10 ns 1Æ13*
*P ¼ 0Æ01; **P < 0Æ01; ns, non-significant. Comparisons are between
adjacent categories; OC, oral contraceptives.
A. Dahm et al
336 ª 2005 Blackwell Publishing Ltd, British Journal of Haematology, 132, 333–338
individuals who had both low TFPI anticoagulant activity and
low chromogenic substrate activity below the 10th percentile,
and found that low levels were associated with an almost
sixfold increase in the risk for DVT. The CI demonstrates the
uncertainty of this risk estimate, and the usefulness of the
combined measures warrants confirmation in other studies.
We also find it interesting that OC use was associated with
the combination of low levels of TFPI anticoagulant activity
and TFPI chromogenic substrate activity in >50% of users,
when compared with <1% in the control subjects not using
OC. These data further substantiate the potential important
role that TFPI may play in increasing the risk of venous
thrombosis in OC users.
Hormonal state had an effect on the normalised TFPI
anticoagulant ratio comparable with that shown previously
(Harris et al, 1999; Hoibraaten et al, 2001; Dahm et al, 2003).
Hormonal state, especially OC use, also affected the normal-
ised dPT by shortening the clotting times. However, addition
of anti-TFPI antibodies that completely ameliorated the effects
of TFPI, resulted in nearly identical clotting times independent
of hormonal state. Hence, the effects of OC and hormonal state
on TF-initiated clotting time can, to a large extent, be
attributed to the effects on full-length TFPI. This is supported
by our recent finding that there was a clear relationship
between the normalised dPT and plasma level of TFPI-free
antigen, but not bound TFPI and anti-TFPI antibodies
repressed this effect (Dahm et al, 2005). This result also
indicates that all assays triggered with TF, e.g. endogenous
thrombin potential-based activated protein C resistance (de
Visser et al, 2005), are possibly affected by the level of full-
length TFPI in the sample assayed.
The fractions of free TFPI in plasma have been estimated by
several authors using different methods (Novotny et al, 1989;
Lindahl et al, 1991; Hansen et al, 1994), and the results have
varied from 3% to 20%. In the present study, the fraction of
free full-length TFPI was approximately 20% using two
different ELISAs with detecting monoclonal antibodies direc-
ted against either the first 160 amino acid residues of the TFPI
molecule in the TFPI total antigen assay or against the last
161–240 residues in the TFPI-free antigen assay (Dahm et al,
2003). We have recently confirmed in vivo (Dahm et al, 2005)
that the full-length TFPI identified by the TFPI-free antigen
assay had the same ability to inhibit coagulation as the full-
length TFPI investigated in vitro (Lindahl et al, 1991, 1992;
Hansen et al, 1994, 1997). Hence, we believe that we have
made a fairly good estimate of the fraction full-length TFPI
circulating in the blood. Hormonal state, especially OC use
influenced the fraction of free TFPI profoundly, which suggests
that hormonal state affects full-length TFPI in plasma more
than truncated TFPI.
The assumption that full-length TFPI is biologically more
important than truncated forms has been based on in vitro
studies, and our study is the first to test this hypothesis in vivo.
Our data suggest that full-length TFPI is not more important
than truncated TFPI in vivo, but that both forms play a role in
the protection against thrombosis. The increased risk related to
the combined measure of the two activity assays suggest that the
ability of TFPI to inhibit either FXa or TF/FVIIa, or both, still
might be important for its anticoagulant effects in vivo. A more
fundamental question is whether circulating TFPI actually plays
any significant role in vivo. It could very well be that the most
important pool of TFPI in vivo is the much larger pool of TFPI
bound to the endothelium. The ORs observed for different
plasma forms of TFPI could possibly be faint, and inaccurate,
reflections of risks connected to the endothelium-associated
TFPI, but this needs investigation in other studies.
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